Spero shares rise premarket after announcing a $105M financing deal and a $1.1B licensing agreement with Innovent Biologics.
Spero Therapeutics (SPRO) shares climbed in premarket trading after securing a licensing agreement worth up to $1.1B with Innovent Biologics (IVBIY) for ex-China rights to an antibody therapy. The deal includes an upfront payment and potential milestones, expanding Spero’s pipeline in oncology and autoimmune diseases.
The agreement follows a $105M financing deal with Healthcare Royalty (HCRX), providing additional capital to support development. Innovent, a leading biopharmaceutical firm, will retain rights within China, while Spero gains global access outside the region.
Premarket gains reflect investor optimism about the partnership’s potential to accelerate Spero’s growth and diversify its portfolio. The deal underscores the company’s strategy to leverage external collaborations for late-stage assets.